CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −2,257 | $30.12 | $68K | 13,301 |
| 2026-11-02 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −336 | $30.91 | $10K | 12,965 |
| 2026-11-02 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −26,563 | $30.10 | $799K | 164,884 |
| 2026-11-02 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −5,345 | $31.05 | $166K | 186,901 |
| 2026-10-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +6,643 | $10.42 | $69K | 38,959 |
| 2026-10-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +857 | $10.42 | $9K | 39,816 |
| 2026-10-29 | Dandekar Atul CSBO | Sale 10b5-1 | −7,500 | $32.07 | $241K | 32,316 |
| 2026-10-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,643 | 0 | ||
| 2026-10-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −857 | 25,073 | ||
| 2026-10-01 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +16,141 | $10.42 | $168K | 16,141 |
| 2026-10-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −16,141 | $26.93 | $435K | 0 |
| 2026-10-01 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,141 | 144,521 | ||
| 2026-10-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −2,593 | $27.02 | $70K | 15,558 |
| 2026-10-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −31,908 | $27.02 | $862K | 191,447 |
| 2026-09-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 39,816 |
| 2026-09-29 | Dandekar Atul CSBO | Sale 10b5-1 | −7,500 | $27.06 | $203K | 32,316 |
| 2026-09-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 6,643 | ||
| 2026-09-04 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −9,705 | $26.22 | $255K | 0 |
| 2026-09-03 | Bernstein Harold President, R&D & CMO | Sale | −5,130 | $26.01 | $133K | 9,764 |
| 2026-09-03 | Bernstein Harold President, R&D & CMO | Sale | −59 | $25.78 | $2K | 9,705 |
Page 1 of 14 · 267 trades